Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Naloxegol and assessments of opioid induced bowel dysfunction
2015-000419-42Phase 2Completed
- Sponsor
- Aalborg University Hospital
- Start
- Feb 2015
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of naloxegol in opioid-induced bowel dysfunction (OIBD) and opioid-induced constipation (OIC), sponsored by Aalborg University Hospital. Primary endpoint: Gastric emptying, small intestinal, and colorectal transit time (MTS-2). Started Feb 2015; status: completed.
02
Drugs
naloxegol
03
Conditions
opioid-induced bowel dysfunction (OIBD)opioid-induced constipation (OIC)
Beyond the preview
Go deeper on 2015-000419-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000419-42.